MERIDIAN BIOSCIENCE, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-11-10: Form 8-K; Period of report 2016-11-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-10-20: Form 8-K; Period of report 2016-10-18; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-10-05: Form 8-K; Period of report 2016-10-05; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2016-07-29: Form 8-K; Period of report 2016-07-26; Description 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-11-10 | 8-K | 2016-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2016, the Company issued a press release commenting on financial results for the fiscal year and fourth quarter ended September 30, 2016. | form8k1116.htm |
| 2016-10-20 | 8-K | 2016-10-18 | 2.02 Results of Operations and Financial Condition | 2.02 On October 18, 2016, the Company issued a press release commenting on preliminary financial results for the fiscal year and fourth quarter ended September 30, 2016. | 8k10182016.htm |
| 2016-10-05 | 8-K | 2016-10-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (e) Effective October 3, 2016, Meridian Bioscience, Inc. (the "Company") and John A. Kraeutler, the Company's Chairman of the Board of Directors, Chief Executive Officer and President, entered into a Third Amended and Restated Employment Agreement (the "Employment Agreement") which, among other things, extends the term of his employment and incorporates the terms and conditions of the Supplemental Benefit Agreement entered into between the Company and Mr. Kraeutler dated June 12, 2012 (the "Supplemental Benefit Agreement"). | form8k100516.htm |
| 2016-07-29 | 8-K | 2016-07-26 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On July 28, 2016, the Company issued a press release announcing its financial results for the third fiscal quarter and nine months ended June 30, 2016. 5.02 On July 26, 2016, the Company and Richard Eberly entered into a letter agreement providing for terms of Mr. Eberly's employment as Corporate Executive Vice President and President, Chief Commercial Officer, responsible for all sales and marketing operations in the core diagnostics and Life Science units, as well as research and development for these units, effective August 1, 2016. | form8k072816.htm |
| 2016-06-06 | 8-K/A | 2016-03-22 | 9.01 Financial Statements and Exhibits | 9.01 On March 24, 2016, Meridian Bioscience, Inc. (“Meridian” or the “Company”) filed a Current Report on Form 8-K (the “Original Filing”) to report the Company’s acquisition of Magellan (defined below) pursuant to the Agreement and Plan of Merger, dated as of March 24, 2016 (the “Merger Agreement”), among Meridian, a merger subsidiary of Meridian (“Merger Sub”), Magellan Biosciences, Inc., a Delaware corporation (“Magellan”), and Ampersand 2006 Limited Partnership, a Delaware limited partnership in its capacity as representative of stockholders (“Stockholder Representative”). | d199340d8ka.htm |
| 2016-04-29 | 8-K | 2016-04-28 | 2.02 Results of Operations and Financial Condition | 2.02 On April 28, 2016, the Company issued a press release announcing its financial results for the second fiscal quarter and six months ended March 31, 2016. | form8k042816.htm |
| 2016-03-24 | 8-K | 2016-03-22 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.01 The information set forth under "Merger Agreement" in Item 1.01 is incorporated herein by reference in its entirety. 2.03 Effective March 22, 2016, the Company entered into the Sixth Amendment to Loan and Security Agreement (the "Sixth Amendment") by and among Fifth Third Bank, an Ohio banking corporation (the "Bank"), Meridian Bioscience Corporation, an Ohio corporation ("MBC"), Omega Technologies, Inc., an Ohio corporation ("Omega"), Meridian Life Science, Inc., a Maine corporation ("MLS"), and Bioline USA, Inc., a Massachusetts corporation ("Bioline"). 8.01 On March 24, 2016, the Company issued a press release announcing the Merger Agreement. | form8k032416.htm |
| 2016-02-01 | 8-K/A | 2015-08-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As previously reported in a Current Report on Form 8-K filed on August 17, 2015, the Board of Directors (the "Board") of the Registrant elected Catherine A. Sazdanoff and John C. McIlwraith to serve on the Board, effective August 14, 2015. | form8ka081715.htm |